세계 줄기세포 치료 시장은 2024년에 164억 4,000만 달러에서 2033년에는 456억 9,000만 달러에 달할 것으로 예상되며, 예측 기간인 2025년부터 2033년까지 12.7%의 CAGR로 성장할 것으로 예상됩니다.
줄기세포 치료는 다양한 질병이나 질환의 예방, 치료, 관리를 위해 줄기세포를 이용한 치료입니다. 줄기세포는 근육, 신경, 혈액세포 등 특수한 세포로 자가 복제 및 분화할 수 있는 독특한 미분화 세포입니다. 줄기세포 치료의 일차적인 목표는 이러한 세포의 재생 특성을 이용하여 손상된 조직을 복구하거나 대체함으로써 현재 치료 옵션이 제한적인 질환을 가진 환자의 건강 상태를 개선하는 것입니다.
줄기세포에는 환자 자신의 몸에서 채취한 자가 줄기세포와 공여자로부터 채취한 동종 줄기세포가 있습니다. 줄기세포 치료는 줄기세포의 고유한 특성을 활용하여 복잡한 건강 문제를 해결하고 환자의 삶의 질을 향상시키는 것을 목표로 하는 재생의료의 유망한 분야입니다. 연구가 진행됨에 따라 이 혁신적인 접근법은 현재 효과적인 치료법이 없는 다양한 질환의 치료에 큰 진전을 가져올 수 있는 잠재력을 가지고 있습니다. 이러한 요인들이 줄기세포 치료 세계 시장 확대의 원동력이 되고 있습니다.
촉진요인과 억제요인
재생의료의 발전
재생 의학의 발전은 줄기세포 치료 세계 시장의 성장 촉진요인이며, 환자 치료 결과를 개선하기 위한 혁신적인 기술과 기술의 지속적인 발전과 통합을 촉진하고 있습니다. 이 분야는 손상된 조직과 장기의 복구, 대체, 재생에 초점을 맞추고 있으며, 줄기세포의 독특한 재생 특성으로 인해 줄기세포가 자주 활용되고 있습니다.
최근 몇 년간 줄기세포의 분화 능력과 본질적인 복구 메커니즘 등 줄기세포의 생물학적 특성에 대한 이해가 크게 향상되었습니다. 이러한 지식은 줄기세포의 재생 능력을 활용하여 기존 의약품으로 충분히 치료할 수 없는 만성질환이나 부상을 치료할 수 있는 효과적인 치료법을 개발하는 데 필수적입니다.
CRISPR과 같은 유전자 편집 기술의 발전은 조직공학의 혁신과 함께 치료 목적으로 줄기세포를 조작하는 능력을 향상시키고 있습니다. 3차원 오가노이드와 스캐폴드의 개발로 자연 조직 환경을 모방하여 보다 효과적인 조직 재생이 가능해졌습니다. 이러한 발전은 환자 개개인의 필요에 따라 맞춤형 치료가 가능한 맞춤형 의료를 실현합니다.
또한, 이 산업의 주요 기업들의 기술 발전과 혁신은 이 세계 줄기세포 치료 시장의 성장을 촉진할 것으로 보입니다. 예를 들어, 2024년 7월 STEMCELL Technologies는 세포 공학 연구와 다양한 질병에 대한 혁신적인 세포 치료의 창출을 촉진하는 것을 목표로 하는 혁신적인 기술인 CellPore Transfection System을 발표했습니다. 이 시스템은 세포 도입법의 큰 진보를 의미합니다.
2024년 1월, Therapeutic Solutions International, Inc.(TSOI)는 간질 치료를 위한 성인 줄기세포 치료의 발전에 초점을 맞춘 새로운 자회사 Epilepsy Bio, Inc. 이 이니셔티브는 간질이라는 신경질환 치료를 위한 세포 및 면역학적 전략에 대한 지적 재산과 임상적 인사이트를 활용한다는 TSOI의 광범위한 사명에 부합하는 것입니다. 이러한 모든 요인들이 세계 줄기세포 치료 시장에 대한 수요를 창출하고 있습니다.
또한, 기술 발전에 따른 성장에 대한 수요 증가도 세계 줄기세포 치료 시장 확대에 기여하고 있습니다.
높은 치료비
치료 비용의 상승은 줄기세포 치료 세계 시장에서 큰 제약이 되고 있으며, 환자 접근성과 시장 성장에 영향을 미치고 있습니다. 줄기세포 치료의 잠재적 이점에도 불구하고 줄기세포 치료의 경제적 부담은 환자와 의료 서비스 제공자 모두에게 이 혁신적인 치료법에 대한 동기를 떨어뜨릴 수 있습니다.
DVC에 따르면, 줄기세포 치료 비용은 다양한 요인에 따라 5,000달러에서 50,000달러까지 다양합니다. 이러한 차이는 환자나 의료 서비스 제공자가 잠재적인 혜택에도 불구하고 이 혁신적인 치료법을 받는 것을 주저하게 만들 수 있습니다. 줄기세포 치료는 종종 특수 장비와 고도로 훈련된 인력을 필요로 하는 복잡한 절차가 수반되는 경우가 많습니다.
줄기세포를 채취하고, 가공하고, 투여하는 것과 관련된 비용은 상당할 수 있습니다. 예를 들어, 기본적인 관절 주사의 경우 1,000달러 정도면 충분하지만, 보다 복잡한 치료의 경우 그 내용에 따라 10만 달러가 넘을 수도 있습니다. 따라서 위와 같은 요인들이 세계 줄기세포 치료 시장의 잠재적 성장을 제한할 수 있습니다.
The global stem cell therapy market reached US$ 16.44 billion in 2024 and is expected to reach US$ 45.69 billion by 2033, growing at a CAGR of 12.7 % during the forecast period 2025-2033.
Stem cell therapy is a medical treatment that employs stem cells to prevent, treat, or manage a variety of diseases and conditions. Stem cells are unique, undifferentiated cells capable of self-renewal and differentiation into specialized cell types, such as muscle, nerve, or blood cells. The primary goal of stem cell therapy is to harness the regenerative properties of these cells to repair or replace damaged tissues, thereby improving health outcomes for patients with conditions that currently have limited treatment options.
Types of stem cells include autologous stem cells which are harvested from the patient's own body and allogeneic stem cells which are sourced from a donor. Stem cell therapy represents a promising frontier in regenerative medicine, aiming to leverage the unique properties of stem cells to address complex health challenges and enhance patient quality of life. As research progresses, this innovative approach holds the potential for significant advancements in treating a variety of conditions that currently lack effective therapies. These factors have driven the global stem cell therapy market expansion.
Market Dynamics: Drivers & Restraints
Advancements in Regenerative Medicine
Advancements in regenerative medicine are a crucial driver of growth in the global stem cell therapy market, the ongoing evolution and integration of innovative techniques and technologies aimed at enhancing patient outcomes. This field focuses on repairing, replacing, or regenerating damaged tissues and organs, frequently utilizing stem cells due to their unique regenerative properties.
Recent research has significantly improved our understanding of stem cell biology, including their differentiation capabilities and intrinsic repair mechanisms. This knowledge is essential for developing effective therapies that can leverage the regenerative potential of stem cells to treat chronic diseases and injuries that traditional pharmaceuticals cannot adequately address.
Advances in gene editing technologies, such as CRISPR, alongside innovations in tissue engineering, have enhanced the ability to manipulate stem cells for therapeutic purposes. The development of three-dimensional organoids and scaffolds allows for more effective tissue regeneration by mimicking natural tissue environments. These advancements enable personalized medicine approaches, where treatments can be tailored to individual patient needs.
Furthermore, key players in the industry's technological advancements and innovations would drive this global stem cell therapy market growth. For instance, in July 2024, STEMCELL Technologies introduced the CellPore Transfection System, an innovative technology aimed at advancing cell engineering research and the creation of innovative cell therapies for various diseases. This system signifies a major advancement in cellular delivery methods.
Also, in January 2024, Therapeutic Solutions International, Inc. (TSOI) announced the formation of Epilepsy Bio, Inc., a new subsidiary focused on advancing adult stem cell therapies aimed at curing epilepsy. This initiative aligns with TSOI's broader mission to utilize its intellectual property and clinical insights related to cellular and immunological strategies for treating this neurological condition. All these factors demand the global stem cell therapy market.
Moreover, the rising demand for the growth of advancements in technology contributes to the global stem cell therapy market expansion.
High Treatment Costs
High treatment costs are a significant constraint in the global stem cell therapy market, affecting patient access and overall market growth. The financial burden associated with stem cell therapies can discourage both patients and healthcare providers from pursuing these innovative treatments, despite their potential benefits.
According to the DVC, stem data stated that the costs associated with stem cell therapies can vary widely, ranging from $5,000 to USD 50,000, depending on various factors. This variability can deter patients and healthcare providers from pursuing these innovative treatments, despite their potential benefits. Stem cell therapies often involve intricate procedures that require specialized equipment and highly trained personnel.
The costs associated with harvesting, processing, and administering stem cells can be substantial. For instance, basic joint injections may cost up to $1,000, while more complex treatments can exceed $100,000, depending on the specifics of the therapy. Thus, the above factors could be limiting the global stem cell therapy market's potential growth.
The global stem cell therapy market is segmented based on therapy type, cell source, therapeutic application, and region.
The allogeneic stem cell therapy segment is expected to dominate the global stem cell therapy market share
The allogeneic stem cell therapy segment holds a major portion of the global stem cell therapy market share and is expected to continue to hold a significant portion of the global stem cell therapy market share during the forecast period.
Allogeneic stem cell therapy is a critical segment of the global stem cell therapy market, involving the use of stem cells obtained from a donor to treat various medical conditions, particularly blood disorders and cancers. This approach differs from autologous stem cell therapy, where the patient's cells are utilized. Allogeneic stem cell therapy relies on stem cells sourced from a donor, which can be either a related individual (such as a sibling) or an unrelated person. The ideal donor typically has a compatible tissue type, defined by human leukocyte antigens (HLAs). If no suitable family member is available, donors can be identified through bone marrow registries.
The allogeneic segment of stem cell therapy is gaining popularity due to its scalability and "off-the-shelf" availability. Unlike autologous therapies that require time-consuming cell collection and processing from individual patients, allogeneic therapies can be prepared in advance from healthy donors and stored for immediate use. This aspect significantly enhances accessibility for patients in urgent need of treatment.
Furthermore, key players in the industry product launches & approvals that would drive this segment growth in the global stem cell therapy market. For instance, in April 2023, the U.S. Food and Drug Administration (FDA) approved Omisirge (generic name: omidubicel-onlv), a modified allogeneic cord blood-based cell therapy designed to expedite the recovery of neutrophils, a critical type of white blood cell essential for fighting infections. This therapy is intended for adults and pediatric patients aged 12 years and older who have blood cancers and are scheduled to undergo umbilical cord blood transplantation following a myeloablative conditioning regimen, which typically includes treatments such as chemotherapy or radiation.
Also, in September 2024, Poseida Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational allogeneic CAR-T cell therapy based on stem cell memory T cells (TSCM). This therapy is currently in Phase 1/1b clinical development for treating patients with relapsed or refractory multiple myeloma, a challenging type of blood cancer. These factors have solidified the segment's position in the global stem cell therapy market.
North America is expected to hold a significant position in the global stem cell therapy market share
North America holds a substantial position in the global stem cell therapy market and is expected to hold most of the market share. The rise in chronic conditions, including cancer, cardiovascular diseases, and musculoskeletal disorders, significantly boosts the demand for stem cell therapies.
The demographic shift towards an older population is contributing to the demand for regenerative medicine. Projections suggest that the number of adults aged 65 and older will increase from approximately 56 million in 2020 to 73 million by 2030, creating a heightened need for treatments targeting age-related health issues. There has been significant investment in stem cell research, exceeding $12 billion in 2023, which is fostering innovation and development in this field. The number of clinical trials has risen by 28% annually, indicating a robust pipeline of new therapies.
Furthermore, advancements in manufacturing and preservation technologies are enhancing the viability and application of stem cell therapies. The Regenerative Medicine Advanced Therapy (RMAT) designation is an important regulatory framework established by the FDA as part of the 21st Century Cures Act. This designation is designed to accelerate the development and review processes for regenerative medicine therapies, including stem cell therapies, that are intended to treat serious or life-threatening conditions.
Moreover, a major number of key players are present, research activities, and product launches & approvals that would drive this global stem cell therapy market. For instance, in November 2024, the University of Texas MD Anderson Cancer Center launched the Institute for Cell Therapy Discovery & Innovation, an initiative focused on advancing impactful cell therapies for a range of conditions, including cancer and autoimmune diseases. This initiative underscores MD Anderson's commitment to leading the field of cell therapy.
Also, in November 2024, GIOSTAR (Global Institute of Stem Cell Therapy and Research) announced that it had received FDA clearance for its Investigational New Drug (IND) application, allowing the company to begin a Phase 2 clinical trial for its innovative stem cell therapy targeting Type II diabetes. This therapy, known as DT2-SCT, utilizes autologous mesenchymal stem cells sourced from the patient's visceral tissues to mitigate the systemic effects of diabetes. Thus, the above factors are consolidating the region's position as a dominant force in the global stem cell therapy market.
Asia Pacific is growing at the fastest pace in the global stem cell therapy market share
Asia Pacific holds the fastest pace in the global stem cell therapy market and is expected to hold most of the market share.
The region's large and aging population contributes to an increased prevalence of age-related diseases such as diabetes, cardiovascular diseases, and neurodegenerative disorders. This demographic shift drives the demand for regenerative therapies that can improve health outcomes in older adults. The growing incidence of chronic diseases, including diabetes, cardiovascular diseases, and Alzheimer's disease, significantly boosts the demand for stem cell therapies as potential treatments that can alleviate symptoms or reverse disease progression.
There is a rising need for advanced medical therapies, particularly those utilizing stem cells to address complex health issues. This demand is primarily fueled by the necessity for effective treatments for chronic diseases and conditions that currently lack sufficient therapeutic options.
As public understanding of the benefits and potential of stem cell therapies expands, more patients and healthcare providers are recognizing these treatments as viable options for managing various health conditions. The Asia-Pacific region has sophisticated medical facilities and technology that support the development and application of stem cell therapies. Countries like China and India are making substantial investments in healthcare infrastructure, enhancing research and clinical applications.
Furthermore, major players in the industry have key initiatives and awareness programs that would drive this global stem cell therapy market growth. For instance, in July 2024, Bioserve India introduced a new line of advanced stem cell products designed to enhance scientific research and drug development in the Indian market. This launch is part of a comprehensive strategy aimed at fostering progress in regenerative medicine and therapeutic discovery, underscoring the increasing significance of stem cell technology across various medical disciplines.
Also, in June 2024, a new free stem cell treatment program was launched specifically for elderly women, aimed at addressing health issues commonly associated with aging. This initiative reflects a growing recognition of the potential benefits of stem cell therapies in improving health outcomes and quality of life for older populations. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global stem cell therapy market.
The major global players in the stem cell therapy market include Mesoblast Ltd, Lineage Cell Therapeutics, Inc., BlueRock Therapeutics LP, Orchard Therapeutics plc., Vericel Corporation., CRISPR Therapeutics AG, Fate Therapeutics, Inc., Novartis AG, Bristol Myers Squibb (Juno Therapeutics, Inc.), Bluebird bio, Inc., MEDIPOST Co., Ltd., ANTEROGEN.CO., LTD., CORESTEMCHEMON Inc., PHARMICELL Co., Ltd, and JCR Pharmaceuticals Co., Ltd. among others.
The global stem cell therapy market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
LIST NOT EXHAUSTIVE